Ikarian Capital Portfolio holdings

AUM $307M

AUM

$307M

AUM Growth

-$43.3M (-12%)

Cap. Flow

+$61M

Cap. Flow % of AUM

19.88%

Top 10 Holdings %Top 10 Hldgs %

39.15%

Holding

181

New

Increased

Reduced

Closed

1	SPDR S&P 500 ETF Trust SPY	$14M
2	Akero Therapeutics AKRO	$9.92M
3	Sarepta Therapeutics SRPT	$8.62M
4	Alnylam Pharmaceuticals ALNY	$8.53M
5	Vaxcyte PCVX	$7.55M

1	Tarsus Pharmaceuticals TARS	$6.3M
2	Avalo Therapeutics AVTX	$6.17M
3	Blueprint Medicines BPMC	$4.91M
4	BridgeBio Pharma BBIO	$4.32M
5	Scholar Rock SRRK	$3.63M

#	Name	Market Value	Portfolio Weight	Shares or Principal	Shares Change %	Capital Flow
126	126 Brainstorm Cell Therapeutics BCLI $9.69M	$0	0%	0 -6,016	Closed	–
127	127 Biohaven BHVN $1.74B	$0	0%	0	–	–
128	128 Biomea Fusion BMEA $93.6M	$0	0%	0	–	–
129	129 Candel Therapeutics CADL $303M	$0	0%	0 -1,400	Closed	–
130	130 Cal-Maine CALM $4.76B	$0	0%	0	–	–
131	131 Capricor Therapeutics CAPR $650M	$0	0%	0	–	–
132	132 Perspective Therapeutics CATX $246M	$0	0%	0 -108,300	Closed	–
133	133 Celcuity CELC $494M	$0	0%	0	–	–
134	134 Celldex Therapeutics CLDX $1.42B	$0	0%	0	–	–
135	135 Compass Therapeutics CMPX $346M	$0	0%	0	–	–
136	CMPS 136 Compass Pathways CMPS $449M	$0	0%	0 -202,894	Closed	–
137	137 Corcept Therapeutics CORT $7.38B	$0	0%	0	–	–
138	138 Corbus Pharmaceuticals CRBP $113M	$0	0%	0 -51,431	Closed	–
139	139 Cardiff Oncology CRDF $258M	$0	0%	0 -450,000	Closed	–
140	140 Corvus Pharmaceuticals CRVS $302M	$0	0%	0	–	–
141	141 CytomX Therapeutics CTMX $416M	$0	0%	0 -8,924	Closed	–
142	142 4D Molecular Therapeutics FDMT $202M	$0	0%	0 -40	Closed	–
143	143 Galectin Therapeutics GALT $83.5M	$0	0%	0 -100	Closed	–
144	144 GlycoMimetics GLYC $12.5M	$0	0%	0 -6,501	Closed	–
145	145 Harrow HROW $1.09B	$0	0%	0	–	–
146	146 Immunovant IMVT $2.87B	$0	0%	0 -600	Closed	–
147	147 Incyte INCY $13.3B	$0	0%	0	–	–
148	148 Disc Medicine IRON $1.73B	$0	0%	0	–	–
149	149 Kymera Therapeutics KYMR $3.1B	$0	0%	0	–	–
150	150 Eli Lilly LLY $691B	$0	0%	0	–	–